Agios Pharmaceuticals (AGIO) to Post Quarterly Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is expected to be announcing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Agios Pharmaceuticals to announce earnings of ($1.6548) per share and revenue of $26.3950 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:00 AM ET.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The company had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $13.30 million. The firm’s revenue was up 137.7% on a year-over-year basis. On average, analysts expect Agios Pharmaceuticals to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ:AGIO opened at $35.99 on Wednesday. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00. The company has a market capitalization of $2.14 billion, a P/E ratio of -4.96 and a beta of 0.54. The company has a 50-day simple moving average of $34.24 and a 200 day simple moving average of $30.81.

Analysts Set New Price Targets

Several analysts have issued reports on AGIO shares. JPMorgan Chase & Co. dropped their price objective on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a research note on Thursday, June 11th. Royal Bank Of Canada lifted their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. The Goldman Sachs Group boosted their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Truist Financial raised their price target on Agios Pharmaceuticals from $36.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $40.00.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AGIO. Bellevue Group AG increased its position in Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock worth $149,110,000 after buying an additional 124,586 shares during the period. State Street Corp raised its stake in Agios Pharmaceuticals by 37.4% in the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after purchasing an additional 845,433 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after purchasing an additional 2,049,287 shares during the period. Commodore Capital LP grew its position in shares of Agios Pharmaceuticals by 6.4% during the 2nd quarter. Commodore Capital LP now owns 2,325,000 shares of the biopharmaceutical company’s stock worth $77,330,000 after purchasing an additional 140,000 shares in the last quarter. Finally, TCG Crossover Management LLC increased its holdings in shares of Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock worth $57,402,000 after purchasing an additional 733,038 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.